Search

Displaying results 2671 - 2680 of 6076 in total
  1. Drug

    Copper

    go.drugbank.com/drugs/DB09130
    ApprovedInvestigational

    Copper is a transition metal and a trace element in the body. It is important to the function of many enzymes including cytochrome c oxidase, monoamine oxidase and superoxide dismutase [FDA Label]. Copper is commonly used in contraceptiv...

    Mixtures: For-2, Multivitamins and Minerals for Women
  2. Drug

    Forasartan

    go.drugbank.com/drugs/DB01342
    Experimental

    Forasartan competes with angiotensin II for binding at the AT1 receptor subtype.

  3. Drug

    Encorafenib

    go.drugbank.com/drugs/DB11718
    ApprovedInvestigational

    Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. … [L3344] On June 27, 2018, the Food and Drug Administration approved encorafenib and [binimetinib] (BRAFTOVI and MEKTOVI, Array BioPharma Inc.) in combination for patients with unresectable or metastatic

  4. Drug

    GI-5005

    go.drugbank.com/drugs/DB05942
    Investigational

    GI-5005 is GlobeImmune's lead infectious disease product from its proprietary Tarmogen active immunotherapy platform for the treatment of chronic hepatitis C infection.

  5. Drug

    Vanoxerine

    go.drugbank.com/drugs/DB03701
    Investigational

    It was synthesized in the late 1970s and developed as a potential treatment for depression. … [A248555] Vanoxerine is an investigational drug and has not been approved for therapeutic use.

  6. Drug

    Methdilazine

    go.drugbank.com/drugs/DB00902
    Approved

    Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus.

    Categories: Antihistamines for Systemic Use
  7. Drug

    Allogenic Donor CD362-enriched Human Umbilical Cord-derived Mesenchymal Stem Cells

    go.drugbank.com/drugs/DB15731
    Investigational

    Enrichment of CD362 expression in MSCs is being investigated for its role in immune modulation of injured tissue. … mesenchymal stem cells (UC-MSCs); UC-MSCs share stemness markers with both embryonic stem cells (ESCs) and adult mesenchymal stem cells (MSCs); this feature allows them to be hypoimmunogenic and non-inducible for

  8. Drug

    Mupadolimab

    go.drugbank.com/drugs/DB16488
    Investigational

    NCT04464395 and NCT04734873 assessed its use for hospitalized COVID-19 patients alone or with standard care.

    Categories: Experimental Unapproved Treatments for COVID-19
  9. Drug

    Tiratricol

    go.drugbank.com/drugs/DB03604
    ApprovedInvestigational

    [L53383] It was first approved by the EMA on February 12, 2025 for the treatment of peripheral thyrotoxicosis in patients with monocarboxylate transporter 8 (MCT8) deficiency,[A274038] a disorder characterized

  10. Drug

    Hydrocortamate

    go.drugbank.com/drugs/DB00769
    Approved

    Hydrocortamate is a synthetic glucocorticoid used for its anti-inflammatory or immunosuppressive properties to treat inflammation due to corticosteroid-responsive dermatoses.